Potential of GLP-1 Receptor Agonists in Treating Sleep Apnea. Sleep 47(Supplement 1):A265
Actual dosing should always follow provider instructions
Ozempic often used off-label) Tirzepatide (Zepbound / Mounjaro) a dual GLP-1/GIP agonist that tends to produce even greater weight loss Liraglutide (Saxenda) Originally developed for Type 2 diabetes, these medications received Health Canada approval for chronic weight management in adults with a BMI 30, or BMI 27 with at least one weight-related condition (such as hypertension, dyslipidemia, or obstructive sleep apnea)
While some patients and clinics report benefits like more energy or less nausea, no large clinical trials have been conducted to confirm these claims
Direct feedback from their workforce provides insight into how obesity impacts operations and morale, influencing their willingness to cover newer, more expensive therapies like GLP-1s
Nonetheless, comprehensive real-world economic assessments across various healthcare systems are few, highlighting a significant research need for informed policy choices about coverage and accessibility